Published: Jan. 1, 2025
Language: Английский
American Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 182(3), P. 227 - 230
Published: March 1, 2025
Language: Английский
Citations
1
Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown
Published: April 3, 2025
This study investigates the therapeutic effectiveness of intranasal dantrolene nanoparticles pretreatment to inhibit lipopolysaccharide (LPS)-induced pathological inflammation and synapse destruction depressive anxiety behavior in mice. B6SJLF1/J adult mice were pretreated with (dantrolene: 5mg/kg), daily, Monday Friday, 5 days per week, for 4 weeks. Then, treated an intraperitoneal injection LPS (5mg/kg) one time. Behavioral tests depression performed 24 hours after a one-time injection. Biomarkers pyroptosis-related cytokines (IL-1β IL-18) blood brain measured using enzyme-linked immunosorbent assay (ELISA) immunoblotting, respectively. The changes primary proteins activation inflammatory pyroptosis (NLRP3: NLR family pyrin domain containing 3, Caspase-1, N-GSDMD: N terminal protein gasdermin D) (PSD-95 synpatin-1) brains immunoblotting. Intranasal robustly inhibited LPS-induced behavior. significantly elevation IL-1β IL-18 pyroptosis. ameliorated decrease PSD-95 synpatin-1 brains. Thus, have demonstrated neuroprotection against inflammation-mediated behaviors should be studied further as future effective drug treatment major disorder or psychiatric disorder.
Language: Английский
Citations
1
American Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 182(3), P. 223 - 226
Published: March 1, 2025
Language: Английский
Citations
0
Journal of Eating Disorders, Journal Year: 2025, Volume and Issue: 13(1)
Published: March 17, 2025
Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic depression suicidal ideations, could be an innovative adjuvant treatment the AN spectrum. We describe case series eight patients treated with intravenous Ketamine Adjuvant Treatment (KAT) combined usual care. also review literature discuss theoretical mechanisms behind influence KAT EDs. Our were all female, diagnosis spectrum, aged between 16 44. offered attempting to remodel rigid food-centered thoughts. Some sessions guided by psychomotor or psychological support, thus working on self-image, body perceptions, self-esteem, sensorial re-exposure "forbidden" food. improved BMI, coefficient 0.71 (0.23–1.20, p = 0.002), tendency improve weight regain dynamics from fourth fifth infusion onwards. It reduce psychopathology obsessive-compulsive-like symptoms (ruminations, cognitive rigidity, guilt), improving clinical evolution. findings underscore potential approach restrictive EDs after failure first-line treatments. addresses thought patterns neurocognitive biases that are notoriously difficult target. Ketamine's "pro-plasticity" "pro-neurogenesis" properties may facilitate this effect. represents tool Future research controlled studies is imperative corroborate its
Language: Английский
Citations
0
Medicina, Journal Year: 2025, Volume and Issue: 61(4), P. 558 - 558
Published: March 21, 2025
Objective: To narratively review currently available antidepressants and future potential as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), norepinephrine (SNRIs), dopamine inhibitor (bupropion), tricyclic (TCAs), monoamine oxidase (MAOIs) were reviewed according to results from Sequenced Treatment Alternatives Relieve Depression (STAR*D) Study systematic reviews. For rest antidepressants, a PubMed/Medline search was conducted with priority drugs in development disorders, PubMed, Google, Clinicaltrials.gov databases used. Results: The STAR*D demonstrated that sertraline, venlafaxine, bupropion had similar efficacy patients major disorder (MDD) who failed citalopram. A network meta-analyses randomized, placebo-controlled trials found SSRIs, SNRIs, bupropion, TCAs, mirtazapine, agomelatine relative compared placebo, but different acceptability. Gepirone more failed/negative studies smaller effect size placebo other antidepressants. combination dextromethorphan ketamine infusion, intranasal esketamine faster onset action monoamine-based monotherapy. Brexanolone zuranolone are effective postpartum depression (PPD), MDD or adjunctive therapy very small. Psychedelics, glutamate receptor-related agents, kappa opioid receptor antagonists, orexin new anti-inflammatory biomarker-based antidepressant have been under investigation Psychedelics showed action, large size, long durability. Conclusions: Monoamine-based likely continue be mainstream disorder. NMDA antagonists neurosteroid will play bigger role improvement accessibility. may become game changer if phase III validate their safety
Language: Английский
Citations
0
The Lancet Psychiatry, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Citations
0
European Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: 96, P. 12 - 14
Published: April 16, 2025
Language: Английский
Citations
0
Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: April 22, 2025
Language: Английский
Citations
0
Published: Jan. 1, 2025
Language: Английский
Citations
0